Health News Roundup: China OKs its first mRNA vaccine, from drugmaker CSPC; Moderna signs licensing deal with Generation Bio in push beyond COVID and more

In a late stage trial Dupixent, jointly developed with Regeneron, led to a 30% reduction in moderate or severe acute exacerbations of chronic obstructive pulmonary disease (COPD), a potentially deadly disease marked by progressive lung function decline. Masimo CEO waives right to $600 million payout in fight with activist investor Masimo Corp Chief Executive Joe Kiani has waived his rights for roughly $600 million in special payment if the U.S. medical device maker appoints a lead independent director, the company said on Thursday.

Related Keywords

Equatorial Guinea ,France ,China ,El Salvador ,United States ,American ,Salvadoran ,French ,Karen Remley ,Joe Kiani ,Abbvie Parkinson ,Michael Cohen ,Abbvie Inc ,Drug Administration ,Generation Bio Co ,Us Centers For Disease ,Masimo Corp ,Pfizer ,Moderna Inc ,Incyte Corp ,World Health Organization ,Group Ltd ,American Court ,National Center On Birth Defects ,Generation Bio ,Vie Inc ,Inter American Court ,Human Rights ,Corp Chief Executive Joe Kiani ,Disease Control ,National Center ,Birth Defects ,Developmental Disabilities ,Merkel ,Ynyz ,Abbvie ,Dupixent ,Beatriz ,Moderna ,Covid 19 ,Kiani ,Eneration Bio 39 S ,